Long-term results of brentuximab vedotin and bendamustine for first-line treatment of Hodgkin lymphoma in the elderly (HALO trial).
- DOI
- 10.1111/bjh.70763
- Published
- 2026 Aug 26
- Container
- British journal of haematology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1111/bjh.70763,
title = {Long-term results of brentuximab vedotin and bendamustine for first-line treatment of Hodgkin lymphoma in the elderly (HALO trial).},
author = {Gallamini A and Viviani S and Rapezzi D and Patti C and Feugier P and Rambaldi A and Bijou F and Borra A and Borel C and Pace-Loscos T and Schiappa R and Chauvie S and Debaigt C and Guidetti A and Humbert O and De Colella JS},
year = {2026},
journal = {British journal of haematology},
doi = {10.1111/bjh.70763},
url = {https://doi.org/10.1111/bjh.70763}
}RIS
TY - JOUR TI - Long-term results of brentuximab vedotin and bendamustine for first-line treatment of Hodgkin lymphoma in the elderly (HALO trial). AU - Gallamini A AU - Viviani S AU - Rapezzi D AU - Patti C AU - Feugier P AU - Rambaldi A AU - Bijou F AU - Borra A AU - Borel C AU - Pace-Loscos T AU - Schiappa R AU - Chauvie S AU - Debaigt C AU - Guidetti A AU - Humbert O AU - De Colella JS PY - 2026 JO - British journal of haematology DO - 10.1111/bjh.70763 UR - https://doi.org/10.1111/bjh.70763 ER -
APA
A, G., S, V., D, R., C, P., P, F., A, R., F, B., A, B., C, B., T, P., R, S., S, C., C, D., A, G., O, H., & JS, D. C. (2026). Long-term results of brentuximab vedotin and bendamustine for first-line treatment of Hodgkin lymphoma in the elderly (HALO trial).. British journal of haematology. https://doi.org/10.1111/bjh.70763
Source records
- pubmed · retrieved 2026-09-26T02:01:25.005Z